China Market Entry Strategy Case Study

Curation of partnering candidates and detailed revenue forecast to support licensing initiatives

The Situation

A U.S. biotech company seeks to understand China ovarian cancer market situation and to assess potential for a novel therapy among four patient segments in later line treatment

Develop a list of potential partners and prioritize them
Detailed forecast of market opportunities for the four targeted patient segments
An overview of China healthcare landscape, including pricing, reimbursement, and local competition

40+ China-based companies were analyzed for their potential as partners for the China market rights for the asset
We analyzed and recommended top ten partnering candidates

We outlined the pricing and reimbursement environment for oncology drugs
We mapped out detailed clinical pathway for two main types of patients based on treatment guidelines and in-depth interviews with Chinese KOLs
We developed treatment paradigm with patient volume estimations
We constructed a quantitative model based on current treatment paradigm and estimated market opportunities for the novel therapy in each patient segment and line of treatment

Assisted the client in understanding the unique market landscape in China and potential hurdles

Developed fact-based revenue forecast to support term sheet development

Curated potential partners for BD&L initiatives

Bluestar BioAdvisors, LLC

521 Fifth Avenue, 25th Floor
New York, NY USA 10175